Replies to post #3056 on GTC Biotherapeutics (fka GTCB)

[go seek]

We have not seen #1 yet, correct?

Possible and Probable News Flow
(supplement to chart in #msg-16969103):

1. Start of patient enrollment in phase-2 ATryn trial for DIC/sepsis by partner, Leo Pharma. This may not be a large news item per se, but it will help to cement the view that ATryn is more than just the hereditary-deficiency indication. Expect news on this any day inasmuch as GTC reported on the 3/5/07 CC that the clinical-trial sites have already been opened.